Morrison L J, Cochran A J, Baird G M, Campbell A M, Willoughby M L
Am J Pediatr Hematol Oncol. 1982 Spring;4(1):3-9.
Tumor-directed immunity was assessed in 29 patients with neuroblastoma (NB). Cell-mediated and humoral immunity were assessed in vitro using the one-stage direct capillary leukocyte migration inhibition test and the indirect, membrane immunofluorescence test, respectively. Leukocytes from 83% of NB patients, 40% of normal children, and 24% of adults were inhibited by NB-derived materials. NB patients' leukocytes reacted as frequently with materials from allogeneic neuroblastomas as with autologous extracts. Sera from 50% of NB patients, 8% of child controls, and 18% of adult controls reacted with allogeneic tissue cultured neuroblastoma cells. Leukocytes from NB patients, control children, and control adults were inhibited at a similar low frequency by extracts of human melanomas and cancers of cervix, colon, and breast. Sera from NB patients and controls reacted infrequently with cultured melanoma cells.
对29例神经母细胞瘤（NB）患者的肿瘤定向免疫进行了评估。分别使用单阶段直接毛细血管白细胞迁移抑制试验和间接膜免疫荧光试验在体外评估细胞介导免疫和体液免疫。来自83%的NB患者、40%的正常儿童和24%的成人的白细胞受到NB来源物质的抑制。NB患者的白细胞与来自同种异体神经母细胞瘤的物质反应的频率与与自体提取物反应的频率相同。50%的NB患者血清、8%的儿童对照血清和18%的成人对照血清与同种异体组织培养的神经母细胞瘤细胞发生反应。NB患者、对照儿童和对照成人的白细胞受到人类黑色素瘤以及子宫颈癌、结肠癌和乳腺癌提取物抑制的频率相似。NB患者和对照的血清很少与培养的黑色素瘤细胞发生反应。
